Sensorion Names SENS-601 Lead Gene Therapy Program, Files Clinical Trial Applications for GJB2-Related Hearing Loss
Sensorion is focusing on SENS-601 targeting GJB2 mutations, while discontinuing development of its OTOF-targeting program, SENS-501.
Search fresh public links, source activity, and ready-to-use post angles for Gjb2.
Fresh curated links around GJB2 are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Sensorion is focusing on SENS-601 targeting GJB2 mutations, while discontinuing development of its OTOF-targeting program, SENS-501.
In May 2025, a young boy received an injection delivering a healthy copy of a gene called OTOF into the cochlea of his inner ear — one of the first patients with hereditary hearing...
A 6-year-old boy with Cockayne syndrome — a rare genetic disorder that causes hearing loss, vision impairment, and early death — has become the first child to receive an experiment...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.